- Home
- FTHY vs AMLX Comparison
FTHY vs AMLX Comparison
Compare FTHY & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTHY
- AMLX
- Stock Information
- Founded
- FTHY 2020
- AMLX 2014
- Country
- FTHY United States
- AMLX United States
- Employees
- FTHY N/A
- AMLX N/A
- Industry
- FTHY Investment Managers
- AMLX Biotechnology: Pharmaceutical Preparations
- Sector
- FTHY Finance
- AMLX Health Care
- Exchange
- FTHY Nasdaq
- AMLX Nasdaq
- Market Cap
- FTHY 535.0M
- AMLX 481.9M
- IPO Year
- FTHY N/A
- AMLX 2022
- Fundamental
- Price
- FTHY $14.68
- AMLX $5.19
- Analyst Decision
- FTHY
- AMLX Buy
- Analyst Count
- FTHY 0
- AMLX 7
- Target Price
- FTHY N/A
- AMLX $7.60
- AVG Volume (30 Days)
- FTHY 176.7K
- AMLX 1.7M
- Earning Date
- FTHY 01-01-0001
- AMLX 11-07-2024
- Dividend Yield
- FTHY 10.93%
- AMLX N/A
- EPS Growth
- FTHY N/A
- AMLX N/A
- EPS
- FTHY N/A
- AMLX N/A
- Revenue
- FTHY N/A
- AMLX $196,485,000.00
- Revenue This Year
- FTHY N/A
- AMLX N/A
- Revenue Next Year
- FTHY N/A
- AMLX $149.49
- P/E Ratio
- FTHY N/A
- AMLX N/A
- Revenue Growth
- FTHY N/A
- AMLX N/A
- 52 Week Low
- FTHY $12.66
- AMLX $1.58
- 52 Week High
- FTHY $14.74
- AMLX $19.95
- Technical
- Relative Strength Index (RSI)
- FTHY 49.32
- AMLX 50.53
- Support Level
- FTHY $14.61
- AMLX $5.09
- Resistance Level
- FTHY $14.91
- AMLX $5.88
- Average True Range (ATR)
- FTHY 0.14
- AMLX 0.61
- MACD
- FTHY 0.01
- AMLX -0.20
- Stochastic Oscillator
- FTHY 55.77
- AMLX 22.96
About FTHY First Trust High Yield Opportunities 2027 Term Fund
FIRST TRUST HIGH YIELD OPPORTUNITIES 2027 TERM FUND is a diversified, closed-end management investment company. The investment objective of the fund is to provide current income.
About AMLX Amylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder.